Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Medscape Oncologist Lifestyle Report 2015

(Medscape Medical Oncology) Jan 26, 2015 - This Medscape lifestyle survey updates a previous report on oncologists' lifestyle and burnout.

Commentary: Damn, I'm tired...

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Valeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon

(NASDAQ/Dow Jones Business News) Jan 29, 2015 - Valeant Pharmaceuticals International Inc. said late Thursday it has reached a tentative deal to buy the prostate cancer drug Provenge and other assets from Dendreon Corp. for $296 million in cash.
read article »

Enzyme Inhibitor Shines in Polycythemia Vera Trial

(MedPage Today) Jan 29, 2015 - Significantly more patients with inadequately treated polycythemia vera (PCV) achieved protocol-defined disease control with the Janus kinase (JAK) inhibitor ruxolitinib (Jakavi) than with standard therapy, a phase III trial showed.
read article (free registration required) »


View ALL News »

News Story Commentary By Academic and Community Oncologists

Medscape Oncologist Lifestyle Report 2015 (Medscape Medical Oncology)

Damn, I'm tired...posted by: Thomas Marsland, MD

Biosimilar Drugs Promise to Cut Patient Costs, But Will Doctors and Insurers Buy Them? (International Business Times)

Biosimilars present an interesting challenge. Generics are really the same compound, produced in similar fashion...posted by: Thomas Marsland, MD

Will Cancer Society's Redo Be Its Undoing? (MedPage Today)

This report hits especially close to home. This will not be the undoing because the ACS has already been undone....posted by: Thomas Marsland, MD

Digital Sales Tools Are Influencing More Docs to Consider Prescriptions? (Wall Street Journal/Pharmalot blog)

Digital tools have been around for awhile in form of e-prescribing devices, EMRs, decision support tools, and the...posted by: Winston Wong, PharmD

Insight: Safety Concerns Cloud Early Promise of Powerful New Cancer Drugs (Reuters)

Isn't this like any other drug that comes onto the market: weighing efficacy against safety and cost? Stakes are...posted by: Winston Wong, PharmD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.


The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
IMGN +23.06%
LOXO +8.48%
CBMG +7.33%
EPZM -6.82%
GALT -6.67%
SRNE -6.40%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: February 22, 2015
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

Date: March 8, 2015
Company: Novartis / Sandoz
Product: Zarxio™ (filgrastim, EP2006)

Date: March 2015
Company: Nektar Therapeutics
Product: NKTR-102

See All OBR Radar items»